scholarly journals Severe Skin Rash Associated with Atazanavir

2009 ◽  
Vol 20 (1) ◽  
pp. e10-e12 ◽  
Author(s):  
Andrew Walkty ◽  
Dick Smith ◽  
Bernie Lopko ◽  
Ken Kasper

Three cases of severe rash associated with the use of atazanavir are described. In all cases, the rash was maculopapular and pruritic. Rash onset occurred eight to 11 days after initiation of therapy, and resolved with atazanavir discontinuation. Clinicians prescribing atazanavir should be aware of this potential adverse effect.

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Natalie Martos ◽  
William Hall ◽  
Alicia Marhefka ◽  
Thomas W. Sedlak ◽  
Frederick C. Nucifora

Abstract Background Neutropenia, a decrease in total number of neutrophils below 1500/mm3 and particularly severe neutropenia, defined as neutrophils less than 500/mm3, is a potential adverse effect of antipsychotic medications that can lead to increased risk of infections and death. However, much of the attention on the potential adverse effect is centered exclusively on clozapine, which remains the only antipsychotic medication in the United States requiring standardized monitoring of blood work. We demonstrate here that paliperidone can also cause neutropenia and therefore clinicians should be aware of this possibility especially during initiation of treatment. Case presentation The following report presents the case of a 23-year-old African American male with first episode psychosis who developed neutropenia after initiation of paliperidone. Neutropenia resolved after discontinuation of paliperidone and initiation of an alternative antipsychotic, haloperidol. Conclusions This case report demonstrates an example of paliperidone induced neutropenia which resolved with a switch to haloperidol. We conclude that when initiating paliperidone, clinicians should be more aware of the risk of neutropenia. Moreover, neutropenia may be a more common and overlooked issue in patients on antipsychotic medications other than clozapine and increased awareness of comparative risk across antipsychotics could help direct treatment.


2019 ◽  
Vol 6 (7) ◽  
Author(s):  
Said El Zein ◽  
Hussam Tabaja ◽  
Amjad Kanj ◽  
Deborah Richmond ◽  
Jennifer Veltman

Abstract No cases of tenofovir alafenamide (TAF)–induced alopecia have been reported in the literature. We describe 6 cases of hair loss in African American female patients after switching to TAF and aim to raise awareness about this potential adverse effect of TAF, which could predominate in certain patient populations.


Author(s):  
Martin A. Katzman ◽  
Melissa Furtado ◽  
Leena Anand

2013 ◽  
Vol 47 (2) ◽  
pp. 139-143 ◽  
Author(s):  
Alexander Urban ◽  
Marija Kataržytė ◽  
Susanne Schickman ◽  
Katharina Kräutler ◽  
Tony Pla

The role of small mammal mycophagy as vectors of hypogeous fungi is well established. However, little is known about dispersal of gourmet truffle species by mammal vectors, or about the potential role of mycophagy in truffle plantations. We hypothesize that small mammal mycophagy contributes to the productivity of truffle plantations by providing inoculum for truffle mycelium establishment and mating. Spread of non-desired competitors of gourmet truffles is a potential adverse effect of small mammal mycophagy.


2020 ◽  
Vol 7 (1) ◽  
pp. e000533
Author(s):  
Amr Elsayed ◽  
Ehab M Abdelraheem ◽  
Hatem Hassan ◽  
Abbas Abbas ◽  
Alshymaa Hassnine

Hepatitis C virus (HCV) related liver cirrhosis is considered a major health problem; sofosbuvir (SOF)/ledipasvir (LDV) and SOF/daclatsvir (DACLA) are very promising direct antiviral agents (DAAS) especially in treating HCV genotype 4 which is the main genotype in Egypt. Uric acid elevation was reported in many systemic diseases and might be elevated during direct antiviral therapy. The aim is to evaluate efficacy and safety of SOF/LDV and SOF/DACLA plus ribavirin in treating HCV related child A liver cirrhosis and assess hyperuricaemia as a potential adverse effect to this regimen.MethodsThis prospective observatinal study included 128 HCV naive child A cirrhotic patients divided into two groups (77 patients were treated with SOF 400 mg, DACLA 60 mg and ribavirin 600 mg and 51 patients were treated with SOF 400 mg, LDV 90 mg and ribavirin 600 mg) for 12 weeks, during the treatment complete blood count, creatinine, bilirubin, alanine transaminase, aspartate transaminase and serum uric acid were monitored, HCV RNA quantitative PCR at 12 weeks after the end of treatment was done.ResultsResponse to treatment in SOF/LDV (sof/led) group is about (98%), response to treatment in SOF/DACLA (sof/dacla) group is about (96%). Hyperuricaemia was noticed in 17.6% of patients received sof/led and in 15.5% of those received sof/dacla.ConclusionSOF+LDV and SOF+DACLA plus ribavirin regimens are highly effective in treating chronic HCV patients with compensated liver cirrhosis. Hyperuricaemia is considered a potential adverse effect to DAAS containing ribavirin and may lead to serious side effects such as renal impairment.


1988 ◽  
Vol 22 (9) ◽  
pp. 702-703 ◽  
Author(s):  
Bruce H. Ackerman ◽  
Michael E. Townsend ◽  
William Golden ◽  
Ann B. Bryan

Dermatological toxicity has been reported following initiation of therapy with minoxidil, but no cases have been reported following prolonged use. We report the emergence of an erythematous weeping rash with impending exfoliation three years after the initiation of minoxidil therapy. Minoxidil was withdrawn and the patient responded to therapy with topical corticosteroids. Following minor surgery, the patient was inadvertently rechallenged with minoxidil, Within 24 hours of exposure bullous lesions reappeared in the extremities which again resolved with topical corticosteroids. Dermatological lesions observed on this patient were similar to those reported following acute minoxidil exposure and strongly implicate chronic minoxidil therapy.


Hepatology ◽  
2012 ◽  
Vol 55 (6) ◽  
pp. 2042-2043 ◽  
Author(s):  
Nicolas Dupin ◽  
Vincent Mallet ◽  
Agnès Carlotti ◽  
Anaïs Vallet-Pichard ◽  
Stanislas Pol
Keyword(s):  

2014 ◽  
Vol 5 ◽  
Author(s):  
Tamara Van Batenburg-Eddes ◽  
Nikki C. Lee ◽  
Wouter D. Weeda ◽  
Lydia Krabbendam ◽  
Mariette Huizinga

Sign in / Sign up

Export Citation Format

Share Document